KEMSTRO Drug Patent Profile
✉ Email this page to a colleague
When do Kemstro patents expire, and when can generic versions of Kemstro launch?
Kemstro is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in KEMSTRO is baclofen. There are twenty-one drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kemstro
A generic version of KEMSTRO was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
Summary for KEMSTRO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 150 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,146 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KEMSTRO |
| DailyMed Link: | KEMSTRO at DailyMed |
Recent Clinical Trials for KEMSTRO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pennsylvania Department of Health | Phase 2 |
| National Institutes of Health (NIH) | Phase 2 |
| National Institute on Drug Abuse (NIDA) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for KEMSTRO
US Patents and Regulatory Information for KEMSTRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for KEMSTRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for KEMSTRO
See the table below for patents covering KEMSTRO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2525720 | ⤷ Try a Trial | |
| Japan | 2001524956 | ⤷ Try a Trial | |
| Japan | 2012162558 | RAPIDLY DISSOLVING ROBUST DOSAGE FORM | ⤷ Try a Trial |
| European Patent Office | 2266538 | Formule de dosage robuste à dissolution rapide (Rapidly dissolving robust dosage form) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
